



888 16th Street NW
Suite 800
Washington DC 20006
202-463-2080
lungcanceralliance.org

MEDIA ADVISORY

**LUNG CANCER ALLIANCE ENCOURAGED BY PLAN TO SUBMIT
A NEW DRUG APPLICATION FOR XYOTAX™ TO TARGET
SURVIVAL IN WOMEN WITH LUNG CANCER**

XYOTAX™ New Drug Application

On behalf of lung cancer patients, survivors, their caregivers, and those at risk for the disease, the Lung Cancer Alliance is encouraged to learn of Cell Therapeutics Inc.'s (CTI) decision to submit a new drug application (NDA) for XYOTAX to target survival in women with lung cancer.

“We applaud CTI for its interest in better understanding this devastating disease – since lung cancer patients are faced with so few treatment options,” said Laurie Fenton, President of the Lung Cancer Alliance. “While we recognize that there are many more steps to go in this process before we learn for certain whether this drug will improve survival rates for women – we are heartened that CTI would take such initiative. We will continue to monitor this research closely.”

Lung cancer will kill nearly twice as many women as breast cancer this year. More research for lung cancer treatments is essential. The planned submission of this NDA by CTI is a step in the right direction.

About Lung Cancer

Lung cancer is the leading cause of cancer death in the United States, resulting in 30 percent of all cancer deaths and killing more people than breast, prostate, colon, liver, and kidney cancers combined. More than 60 percent of those diagnosed with the disease are former smokers or people who never smoked.

More than half of new lung cancer cases will be diagnosed at a very late stage, with a five year survival rate of only five percent. Traditional treatments for lung cancer include surgery, radiation, and chemotherapy. New targeted medicines provide more options to help people live longer, but more research is needed.

About Lung Cancer Alliance

The Lung Cancer Alliance is the only national non-profit organization solely dedicated to advocating on behalf of people living with cancer, their families and loved ones, and those at risk for the disease.

****Lung Cancer Alliance President, Laurie Fenton, is available for interview and comment.**

Media Contact

Kay Cofrancesco
kcofrancesco@lungcanceralliance.org
(202) 463-2080

###

NO MORE EXCUSES. NO MORE LUNG CANCER.